Novartis boosts companion diagnostics focus with $470M Genoptix buy
This article was originally published in Scrip
Executive Summary
Novartis is beefing up its companion diagnostics capabilities with the $470 million acquisition of Genoptix, a Carlsbad, California-based company providing personalised diagnostic services to community-based haematologists and oncologists.